ICON plc Schedules Second Quarter 2024 Earnings Conference Call

$ICLR
Biotechnology: Commercial Physical & Biological Resarch
Health Care
Get the next $ICLR alert in real time by email

ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, July 25, 2024 at 8:00am ET.

Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call.

About ICON plc

ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 102 locations in 54 countries as at March 31, 2024. For further information about ICON, visit: www.iconplc.com.

This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

ICON/ICLR-G

Get the next $ICLR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ICLR

DatePrice TargetRatingAnalyst
3/21/2025$250.00 → $200.00Buy → Neutral
Goldman
1/7/2025$263.00Outperform
RBC Capital Mkts
10/24/2024$340.00Outperform → Neutral
Robert W. Baird
10/14/2024Neutral
Redburn Atlantic
9/18/2024$379.00Outperform
Leerink Partners
6/6/2024$370.00Buy
Goldman
12/15/2023$357.00Buy
Truist
9/13/2023$306.00Outperform
TD Cowen
More analyst ratings

$ICLR
Press Releases

Fastest customizable press release news feed in the world

See more
  • BetterInvesting™ Magazine Update on Lowe's Cos. (NYSE: LOW) and ICON PLC (NASDAQ: ICLR)

    TROY, Mich., March 24, 2025 /PRNewswire/ -- Lowe's recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Lowe's Cos. (NYSE:LOW) as worthy of further study and has named the company its "Stock to Study" for the June/July 2025 double issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view Lowe's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at: https://ssg.betterinvesting.org/trial/ssgplus/?ticker=LOW. A full

    $ICLR
    $LOW
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    RETAIL: Building Materials
    Consumer Discretionary
  • ICON Becomes the First Large Clinical Research Organization to Fully Integrate Medidata Clinical Data Studio, Streamlining Data Management and Review

    Adoption allows ICON to take full advantage of the Medidata "Data Experience," leveraging AI to unify data sources, standardize outputs, and reduce reconciliation efforts Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced that ICON plc, (NASDAQ:ICLR) a world-leading clinical research organization (CRO) powered by healthcare intelligence, will immediately begin utilizing Medidata Clinical Data Studio on its studies, differentiating ICON as the first large CRO to fully infuse this technology into its clinical workflows. The integration of Clinical Data Studio into ICON's service offerings helps unlock the full

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON plc to Present at Upcoming Investor Conferences

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025 at 8.00 am ET and at the Barclays 27th Annual Global Healthcare Conference on Thursday, March 13, 2025 at 8.30 am ET. Any changes to these events and links to the live webcasts will be posted on the Investor section of our website under "Events". About ICON plc ICON plc is a world-leading healthcare intelligence and clinical research organisation. From molecule to medicine, we advance clinical research providing outsourced services to

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$ICLR
SEC Filings

See more

$ICLR
Leadership Updates

Live Leadership Updates

See more
  • ICON Announces Appointment of Chief Operating Officer

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Barry Balfe as Chief Operating Officer (COO). Barry is a long-tenured ICON employee with over 20 years of service and brings extensive leadership experience and capability to the role of COO. He has held a number of leadership roles across both full service and functional solutions at ICON and has very successfully supported the growth of new and existing customer partnerships. His strong focus and track record on operational excellence, quality & delivery will enable the company to deliver greater value to our customers and further enhance our strategy to

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON Announces Appointment of New Chief Financial Officer

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organisation, today announced the appointment of Nigel Clerkin as its new Chief Financial Officer (CFO). Nigel brings extensive experience and capability to the role of CFO. He commenced his career with KPMG, before joining Elan Corporation where he held a number of roles of increasing responsibility over a fifteen-year career, culminating in the role of group CFO in 2011, which he held until 2014. Nigel then moved to be CFO at ConvaTec, a global medical and technologies company, before becoming UDG Healthcare's CFO in 2018. During his tenure with UDG, he led substantial change and improvement programmes

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Financials

Live finance-specific insights

See more
  • ICON Reports Fourth Quarter and Full Year 2024 Results

    Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing backlog of $24.7 billion, an increase of 1.4% on quarter three 2024 and 8.3% on quarter four 2023. Quarter four revenue of $2,041.1 million, representing a decrease of 1.2% on prior year revenue. Full year revenue of $8,282 million representing a year on year increase of 2.0%. Quarter four adjusted EBITDA of $422.6 million or 20.7% of revenue, an increase of 0.9% on quarter three 2024. Full year adjusted EBITDA of $1,735.8 million or 21.0% of revenue, representing a year on year increase of 2.5%.

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON plc Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading healthcare intelligence and clinical research organisation, today announced that it will release financial results for the fourth quarter and full year 2024 results after the market closes on Wednesday, February 19, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, February 20, 2025 at 8:00am ET. Any changes to these events and links to the live webcasts (where available) will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
  • ICON Reports Third Quarter 2024 Results

    Highlights Net business wins in the quarter of $2,328 million. Reflects a net book to bill in the quarter of 1.15, and a trailing twelve month net book to bill of 1.21. Closing backlog of $24.3 billion, an increase of 2.1% on quarter two 2024 and 9.4% on quarter three 2023. Quarter three revenue of $2,030.0 million. Quarter three adjusted EBITDA of $418.8 million or 20.6% of revenue. GAAP net income for the quarter of $197.1 million or $2.36 per diluted share, an increase of 19.8% on quarter three 2023 diluted earnings per share. Quarter three adjusted net income was $279.2 million or $3.35 per diluted share, an increase of 1.5% on quarter three 2023 adjusted diluted earnings

    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

$ICLR
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more